Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 18 and greater, body weight ≥ 45kg~* Has adequate acoustic windows to enable accurate transthoracic echocardiograms (TTEs)~* Diagnosed with oHCM consistent with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines and satisfy both criteria:~* Has documented left ventricular ejection fraction (LVEF) ≥55%~* NYHA Class II or III~* Has documented oxygen saturation at rest ≥90% at Screening~* Is able to perform an upright CPET and has a respiratory exchange ratio (RER) ≥1.0 at Screening per central reading~Key Exclusion Criteria:~* Known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM, such as Fabry disease, amyloidosis, or Noonan syndrome with LV hypertrophy~* History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to Screening~* History of resuscitated sudden cardiac arrest (at any time) or known history of appropriate implantable cardioverter defibrillator (ICD) discharge for life-threatening ventricular arrhythmia within 6 months prior to Screening~* Paroxysmal, intermittent atrial fibrillation with atrial fibrillation present at Screening~* Persistent or permanent atrial fibrillation not on anticoagulation for at least 4 weeks prior to Screening and/or not adequately rate controlled within 6 months prior to Screening~* Treatment (within 14 days prior to Screening) or planned treatment during the study with disopyramide or ranolazine~* Treatment (within 14 days prior to Screening) or planned treatment during the study with a combination of β-blockers and calcium channel blockers~* LVOT gradient with Valsalva maneuver \<30 mmHg at Screening~* Has been successfully treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \[ASA\]) within 6 months prior to Screening or plans to have either of these treatments during the study~* ICD placement within 2 months prior to Screening or planned ICD placement during the study~* Has a history or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion~* Prior treatment with cardiotoxic agents such as doxorubicin or similar

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mavacamten (MYK-461) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).